Enhance immune function, fights infections, provides cancer treatment support, potentially improve outcomes for patients with COVID-19 and improves immune homeostasis
Sci China Mater, 2024, 67: 37423752 Ai L, Xiao J, Yu J, et al
Giustina A, Mazziotti G, Canalis E
Tesamorelin and CJC-1295 are both GHRH-receptor agonists, but tesamorelin is an FDA-approved drug with replicated Phase 3 trials while CJC-1295 is an unapproved research chemical with two small surrogate-marker studies
Backed by real reviews & real results
From $349 Our physician-guided Ipamorelin peptide therapy programs typically range from 48 weeks and may be discussed with eligible patients seeking recovery support, healthy aging, wellness optimization, and personalized peptide therapy